From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes
American Journal of Perinatology · 01.07.2025 · 42 (09) · 1127-1134
DOI: 10.1055/a-2407-0905 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Perinatology, erschienen am 01.07.2025. Verfasst von Anna Palatnik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin. Hauptthemen laut MEDLINE: Diabetes, Gestational, Hypoglycemic Agents. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The incidence of gestational diabetes mellitus (GDM) continues to increase in the United States and globally. While the first-line treatment of GDM remains diet and exercise, 30% of patients with GDM will require pharmacotherapy. However, many controversies remain over the specific glycemic threshold values at which pharmacotherapy should be started, how intensified the therapy should be, and whether oral agents are effective in GDM and remain safe for long-term offspring health. This review will summarize recently completed and ongoing trials focused on GDM pharmacotherapy, including those examining different glycemic thresholds to initiate therapy and treatment intensity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin.
- Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin.
- Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Women's Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
ORCID-Profile: Anna Palatnik
Förderung
- NICHD NIH HHS
- U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development
Zitieren
APA
Palatnik, A., & Feghali, M. N. (2025). From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes. American Journal of Perinatology, 42(09), 1127-1134. https://doi.org/10.1055/a-2407-0905
Vancouver
Palatnik A, Feghali MN. From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes. American Journal of Perinatology. 2025;42(09):1127-1134. doi:10.1055/a-2407-0905
BibTeX
@article{Palatnik2025,
author = {Palatnik, Anna and Feghali, Maisa N},
title = {From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes},
journal = {American Journal of Perinatology},
year = {2025},
volume = {42},
number = {09},
pages = {1127--1134},
doi = {10.1055/a-2407-0905}
}
EUVIMED